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ttp://dx.doi.org/10.1016/j.jmoldx.2013.11.004Rett syndrome is a dominant X-linked disorder caused by point mutations (approximately 80%)
or by deletions or insertions (approximately 15% to 18%) in the MECP2 gene. It is most common
in females but lethal in males, with a distinctly different phenotype. Rett syndrome patients have
severe neurological and behavioral problems. Clinical genetic testing laboratories commonly use
characterized genomic DNA reference materials to assure the quality of the testing process;
however, none are commercially available for MECP2 genetic testing. The Centers for Disease
Control and Prevention’s Genetic Testing Reference Material Coordination Program, in collabo-
ration with the genetic testing community and the Coriell Cell Repositories, established 27 new
cell lines and characterized the MECP2 mutations in these and in 8 previously available cell lines.
DNA samples from the 35 cell lines were tested by eight clinical genetic testing laboratories
using DNA sequence analysis and methods to assess copy number (multiplex ligation-dependent
probe ampliﬁcation, semiquantitative PCR, or array-based comparative genomic hybridization).
The eight common point mutations known to cause approximately 60% of Rett syndrome cases
were identiﬁed, as were other MECP2 variants, including deletions, duplications, and frame shift
and splice-site mutations. Two of the 35 samples were from males with MECP2 duplications. These
MECP2 and other characterized genomic DNA samples are publicly available from the NIGMS
Repository at the Coriell Cell Repositories. (J Mol Diagn 2014, 16: 273e279; http://dx.doi.org/
10.1016/j.jmoldx.2013.11.004)Supported in part by NIHeNICHD grant U54-61222 (A.K.P.).
The ﬁndings and conclusions in this report are those of the authors and
do not necessarily represent the ofﬁcial position of the Centers for Disease
Control and Prevention or the Agency for Toxic Substances and Disease
Registry.
Disclosures: S.A. and S.B. are employees of GeneDx, Inc., a subsidiary
of BioReference Laboratories; A.M.B.-B. is an employee of Quest Di-
agnostics; T.D.V. is an employee of Ambry Genetics; V.V.Z. is an
employee of LabCorp; and L.H.T. is an employee of Coriell.Rett syndrome is a dominant X-linked disorder usually
caused by point mutations (approximately 80% in classical
and 40% in atypical cases) and deletions or insertions
(approximately 15% to 18% in classical and 3% in atypical
cases) in the MECP2 gene, although patients with mutations
in two other genes, CDKL5 and FOXG1, may also exhibit a
Rett-like phenotype.1,2 MECP2, located on Xq28 and com-
prising four exons, encodes methyl-CpG binding protein 2stigative Pathology
.
Kalman et al(MeCP2). In males, Rett syndrome is usually lethal, because
of abnormal MeCP2 function from the single X chromosome
and severe neonatal encephalopathy, although Rett syndrome
in males with an XXY karyotype has been reported.3 Du-
plications inMECP2 have also been observed, and these can
cause severe neurodevelopmental disability in males.4 The
prevalence of Rett syndrome in females is approximately
1:10,000.5
Girls with classic Rett syndrome (OMIM #312750)
exhibit a rapid decline in language and motor skills at
approximately 1 year of age. These patients exhibit a loss of
acquired purposeful hand use, loss of communication, gait
ataxia and apraxia, and stereotypic hand movements. They
may also exhibit additional symptoms, including bruxism,
seizures, episodic apnea or hyperpnea, abnormal muscle
tone, and often acquired microcephaly.4,6,7
Patients with Rett syndrome can present with various
phenotypes. Those diagnosed with atypical Rett syndrome
may have either more mild or more severe presentation than
patients with the classical form. These patients share some
of the same symptoms with classical Rett syndrome cases,
but must also have some of the additional symptoms listed
above.4,6 Some patients present with only mild learning
disabilities (females) or intellectual disability (males).4,8
Molecular diagnosis of Rett syndrome is performed by
examination of the patient’s DNA for MECP2 mutations,
using a variety of molecular diagnostic methods. Most
MECP2 mutations are sporadic, and testing is performed on
the proband, although predictive prenatal and preimplanta-
tion genetic testing may also be performed. DNA sequence
analysis may detect point mutations and small insertions
and deletions (indels). Larger deletions and duplications
are detected using multiplex ligation-dependent probe am-
pliﬁcation (MLPA), quantitative PCR, and array-based
comparative genomic hybridization (CGH). To date, there
are no US Food and Drug Administration (FDA)eapproved
assays for Rett syndrome. All testing is performed using
laboratory-developed tests.
Reference materials are needed by laboratories to comply
with regulatory and accreditation requirements for assay
development, assay validation, and quality control, and
their use is recommended by professional guidelines for
clinical laboratories [eg, http://www.acmg.net/Pages/ACMG_
Activities/stds-2002/g.htm, last accessed October 16, 2013;
Washington State Legislature, http://www.doh.wa.gov/hsqa/
fsl/lqa_home.htm, last accessed January 11, 2013; College
of American Pathologists http://www.cap.org/apps/cap.portal,
last accessed January11, 2013 (registration required);NewYork
State Clinical Laboratory Evaluation Program, http://www.
wadsworth.org/clep, last accessed January 11, 2013).9e15
Clinical genetic testing laboratories commonly use character-
ized genomic DNA reference materials to assure the quality of
the testing process. Ideally, these reference materials should
closely resemble patient samples containing variants and types
of variants common to the disorder and should be thoroughly
characterized using methods different from those used in the274user’s laboratory.15 ForRett syndrome, genomicDNAreference
materials derived from females (and, if possible, males) con-
tainingcommonpointmutations, indels, and larger deletions and
duplications should be used. Careful use of a well-characterized
and comprehensive set of reference materials helps to assure the
proper design and function of a clinical assay. To date, there are
no commercially available reference materials for Rett syn-
drome genetic testing.
To address the need for characterized genomic DNA
reference materials for Rett syndrome testing, the Centers for
Disease Control and Prevention (CDC) based Genetic Testing
Reference Material Coordination Program (GeT-RM), in
collaboration with members of the genetic testing community
and the National Institute of General Medical Sciences
(NIGMS) Repository at the Coriell Cell Repositories, have
characterized the MECP2 mutations in 35 publicly available
cell lines. Twenty-seven of the 35 cell lines were generated as
part of this project, using blood collected with informed con-
sent from Rett syndrome patients with variants not previously
represented in cell lines at the Coriell Repository. The avail-
ability of a renewable source of characterized reference ma-
terials for Rett syndrome helps to assure the accuracy of these
genetic tests and facilitate research and test development.
Materials and Methods
Selection of Pre-Existing Cell Lines
Based on preliminary information from the Coriell Cell
Repository and data generated before this study, eight cell
lines (Table 1) with common point mutations or exon de-
letions in the MECP2 gene known to cause Rett syndrome
were selected for further characterization.
Anonymous Blood Collection from Consenting Patients
with Rett Syndrome
Collaboration was established with a researcher (A.K.P.) at
the University of Alabama, Birmingham, to generate new cell
lines with point mutations, duplications, and deletions not
then available in the Coriell Repository collection. A protocol
was developed for anonymous contact, informed consent, and
blood collection from Rett syndrome patients and was
approved by the University of Alabama Institutional Review
Board. Rett syndrome patients previously enrolled in the NIH
Ofﬁce of Rare Diseases Research (ORDR) and National
Institute of Child Health andHumanDevelopment (NICHD)-
sponsored Rare Disease Clinical Research Center Natural
History Study (RDCRC NHS) consortium for Angelman,
Rett, and Prader-Willi Syndromes Natural History study with
requisite Rett syndrome genotypes not represented in the
Coriell Repository collection (common MECP2 point muta-
tions andMECP2 deletions and duplications) were contacted
and asked to participate by UAB staff associated with the
RDCRC study. Recruitment letters describing the study were
sent to eligible Rett syndrome patients, along with otherjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Previously Established Cell Lines Tested at Seven Clinical Genetic Testing Laboratories (Round 1)
Coriell
cell liney
Consensus
genotype
Laboratory and analysis
1: Array
CGH 2: DNA seqz
3: DNA seq;
PCR dosage
4: DNA seq;
MLPA 5: DNA seq
6: DNA seq;
MLPA 7: DNA seq
GM11299 c.316C>T;
p.R106W het
ND c.316C>T;
p.R106W het
c.316C>T;
p.R106W het
ND c.316C>T;
p.R106W het
ND c.316C> T;
p.R106W het
GM11310 c.502C>T;
p.R168* het
ND c.502C>T;
p.R168* het
c.502C>T;
p.R168* het
ND c.502C>T;
p.R168* het
c.502C>T;
p.R168* het
c.502C>T;
p.R168* het
GM16270 c.763C>T;
p.R255* het
ND c.763C>T;
p.R255* het
c.763C>T;
p.R255* het
ND c.763C>T;
p.R255* het
c.763C>T;
p.R255* het
c.763C>T;
p.R255* het
GM16271 c.473C>T;
p.T158M het
ND c.473C>T;
p.T158M het
ND ND ND c.473C>T;
p.T158M het
c.473C>T;
p.T158M het
GM16480 c.916C>T;
p.R306C het
No del/dup
identified
c.916C>T;
p.R306C het
ND c.916C>T;
p.R306C het
ND c.916C>T;
p.R306C het
c.916C>T;
p.R306C het
GM16546 c.880C>T;
p.R294* het
ND c.880C>T;
p.R294* het
ND c.880C>T;
p.R294* het
ND c.880C>T;
p.R294* het
c.880C>T;
p.R294* het
GM17540 c.401C>G
p.S134C het
ND c.401C>G
p.S134C het
ND c.401C>G
p.S134C het
ND c.401C>G
p.S134C het
c.401C>G
p.S134C het
GM11313 EX3_4del het EX3_4del
het
ND EX3_4del het ND No seq var
identified
EX3_4del het ND
yAll cell lines are female.
zExons 2 to 4 only.
del, deletion; dup, duplication; EX3_4del, gross deletion of exons 3 and 4 in MECP2; het, heterozygous; ND, no data (sample not tested in this laboratory);
seq, sequencing; var, variant.
Reference Materials for Rett Syndromeinformational materials, a consent form/waiver of assent
form, and a contact information form. Interested participants
returned completed documents and received a research code
and a blood collection kit. Blood samples collected during
routine health care visits were coded and were sent, without
identiﬁers and using preaddressed, prepaid shipping con-
tainers, to the Coriell Cell Repository for lymphoblastoid cell
line development. Through this process, 33 blood samples
were received and 30 new cell lineswere generated. For two of
these lines, GM23675 and GM23734, the blood samples were
from male patients with duplications of theMECP2 gene.
Cell Line Generation
EpsteineBarr virus transformation of B lymphocytes was
performed on whole-blood samples collected from consent-
ing patients or their families, as described previously.16,17
DNA Preparation
Approximately 2 mg of DNA was prepared from cultures of
each of the selected cell lines by the Coriell Cell Repositories
using the Gentra Autopure method (Qiagen, Valencia, CA)
according to the manufacturer’s instructions or using
methods described previously.18
Testing Laboratories
Eight College of American Pathologistseaccredited clinical
genetic testing laboratories were contacted and volunteered
to test the DNA samples using their current MECP2 assay
methods. Laboratories 1 to 7 participated in Round 1 ofThe Journal of Molecular Diagnostics - jmd.amjpathol.orgtesting (characterization of eight previously available cell
lines) and Laboratories 1 to 5 and 8 participated in Round 2
(testing of the newly generated cell lines). Each sample was
tested at three to ﬁve laboratories in Round 1 and at two or
three laboratories in Round 2 (Tables 1 and 2).
Protocol
The volunteer clinical laboratories received a 10-mg aliquot of
DNA from each of the cell lines for MECP2 testing. The
expected mutation in each of the samples was not revealed to
the laboratories in advance. Each laboratory genotyped the
samples using their standardMECP2DNAsequencing and/or
deletioneduplication assay. The results were sent to the study
coordinator (L.V.K.), who examined the data for discrep-
ancies. Testing was performed in two rounds. In the ﬁrst
round, aliquots of DNA from each of the eight existing Coriell
cell lines (Table 1) were sent to seven laboratories. In Round 2
testing, DNA samples from 27 of the 30 cell lines generated
from Rett syndrome patients for this project (Table 2) were
sent for analysis to six laboratories (including one newly
participating laboratory). DNA from the remaining three
newly generated cell lines was not used, either because it was
not available when the study began or because the expected
mutation could not be conﬁrmed during initial analysis before
the study.
Assays Used in Rounds 1 and 2
DNA sequence analysis, array CGH, MLPA, and PCR
dosage analysis were used to analyze the samples (Tables 1
and 2).275
Table 2 Newly Established Cell Lines Tested at Six Clinical Genetic Testing Laboratories (Round 2)
Coriell
catalog
no. Sex
Consensus
genotype
Laboratory and analysis
1: DNA seq;
MLPA 2: DNA seq; MLPA
3: DNA seq;
PCR dosage
4: DNA seq;
MLPA
5: DNA seq;
MLPA
8: DNA seq;
MLPA
GM23459 F del 50 exon 4
het
NDy ND c. 1226_
1337del 50
exon 4 hetz
ND ND del 50 exon 4 het
GM23461 F c.455C>G;
p.P152R het
ND c.455C>G; p.P152R
het, MLPA neg
ND ND ND c.455C>G; p.P152R
het
GM23462 F c.808C>T;
p.R270* het
ND ND ND c.808C>T;
p.R270*
het
ND c.808C>T; p.R270*
het
GM23463 F c.1173_1207del
p.Glu392* het
ND c.1173_1207del,
p.Glu392*, MLPA
neg
c.1173_
1207del
p.Glu392*
het
ND ND ND
GM23503 F c.806delG; p.
Gly269Alafs*20
het
ND c.806delG;
p.Gly269Alafs*20
het, MLPA neg
ND ND ND c.806delG; p.
Gly269Alafs*20
het
GM23598 F c.808C>T;
p.R270* het
ND c.808C>T; p.R270*
het, MLPA neg
ND ND ND c.808C>T; p.R270*
het
GM23599 F del exon 3e4 het ND del exon 3e4 het,
seq neg
ND ND ND del exon 3e4 het
GM23605 F c.421C>G;
p.Y141* het
c.421C>G;
p.Y141* het
ND ND ND ND c.421C>G; p.Y141*
het
GM23606 F c.27-8C>G (intron
2 IVS8C>G) het
ND c.27-8C>G (intron
2 IVS8C>G)
het, MLPA neg
ND ND ND c.27-8C>G (intron
2 IVS8C>G)
het
GM23607 F c.1157_1200del44;
p.L386Gfs*4 het
ND c.1157_1200del44;
p.L386Gfs*4
het, MLPA neg
ND ND c.1157_
1200del44;
p.L386Gfs*4
het
c.1157_1200del44;
p.L386Gfs*4 het
GM23624 F c.398G>C;
p.R133P het
ND c.398G>C; p.R133P
het, MLPA neg
ND ND ND c.398G>C; p.R133P
het
GM23625 F c.808C>T;
p.R270* het
ND c.808C>T; p.R270*
het, MLPA neg
ND ND ND c.808C>T; p.R270*
het
GM23626 F c.455C>G;
p.P152R het
ND ND ND ND c.455C>G;
p.P152R het
c.455C>G; p.P152R
het
GM23634 F c.397C>T;
p.R133C het
ND c.397C>T; p.R133C
het, MLPA neg
ND ND ND c.397C>T; p.R133C
het
GM23635 F del exon 3 and
part of exon
4, het
ND ND ND del exon 3
and part
of exon
4, het
ND del exon 3 and part
of exon 4, het
GM23647 F c.378-3C>G
(IVS3-3) het
c.378-3C>G
(IVS3-3) het
ND ND ND ND c.378-3C>G
(IVS3-3) het
GM23648 F del exon 4 into
IRAK1, het
ND ND del exon 4
into IRAK1,
het
ND ND del exon 4 into
IRAK1, het
GM23654 F del exon 3 and
part of exon
4, het
ND ND del exon 3 and
part of exon
4, het; dupl
30 end of
exon 4z
ND ND del exon 3 and part
of exon 4, het
GM23659 F c.397C>T;
p.R133C het
c.397C>T;
p.R133C het
ND ND ND ND c.397C>T;
p.R133C
het
GM23663 F c.397C>T;
p.R133C het
ND ND ND c.397C>T;
p.R133C
het
ND c.397C>T;
p.R133C
het
(table continues)
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Table 2 (continued )
Coriell
catalog
no. Sex
Consensus
genotype
Laboratory and analysis
1: DNA seq;
MLPA 2: DNA seq; MLPA
3: DNA seq;
PCR dosage
4: DNA seq;
MLPA
5: DNA seq;
MLPA
8: DNA seq;
MLPA
GM23675 M Complete MECP2
dupl þ dupl of
ﬂanking IRAK1
(exons 3, 4)
ND Complete MECP2
dupl þ dupl of
ﬂanking IRAK1
(exons 3, 4)
ND ND ND Complete MECP2
dupl þ dupl of
ﬂanking IRAK1
(exons 3, 4)
GM23676 F Complete MECP2
dupl þ dupl of
ﬂanking IRAK1,
het
ND ND ND ND Complete MECP2
dupl þ dupl
of ﬂanking
IRAK1, het
Complete MECP2
dupl þ dupl of
ﬂanking IRAK1,
het
GM23733 F Complete MECP2
dupl þ dupl of
ﬂanking FLNA-
MECP2-IRAK1-
L1CAM, het
ND ND MECP2 dupl
exons 2e4
(bp 83,700e
21,600)
ND ND Complete MECP2
dupl þ dupl of
ﬂanking FLNA-
MECP2-IRAK1-
L1CAM, het
GM23734 M Complete MECP2
dupl þ dupl of
ﬂanking FLNA-
MECP2-IRAK1-
L1CAM
ND MECP2 dupl; FLNA
(exon 29) dupl;
IRAK1 (exon 3,
4) dupl; L1CAM
(exon 23) dupl
ND ND ND Complete MECP2
dupl þ dupl of
ﬂanking FLNA-
MECP2-IRAK1-
L1CAM
GM23747 F c.806delG; p.
Gly269Alafs*20
het
ND ND ND ND c.806delG; p.
Gly269Alafs*
20 het
c.806delG;
p.Gly269Alafs*20
het
GM23748 F c.806delG; p.
Gly269Alafs*20
het
ND c.806delG;
p.Gly269Alafs*20
het, MLPA neg
ND ND ND c.806delG;
p.Gly269Alafs*20
het
GM23846 F c.1163_1188del26;
p.Pro388Argfs*7
het
c.1163_
1188del26; p.
Pro388Argfs*7
het
ND ND ND ND c.1163_1188del26;
p.Pro388Argfs*7
het
Laboratories 6 and 7 did not participate in Round 2.
yDeletion 23,700 to 22,200; duplication 21,900 to 21,600.
zSequencing and PCR dosage.
F, female; M, male; dupl, duplication; het, heterozygous; ND, no data (sample not tested in this laboratory); neg, negative; seq, sequencing.
Reference Materials for Rett SyndromeDNA Sequence Analysis
The sequence of exons 1 to 4 of the MECP2 gene was
determined using bidirectional Sanger sequencing with
either ﬂuorescently tagged primers or dideoxy termina-
tors. The reactions were analyzed using capillary
electrophoresis.
DeletioneDuplication Analysis
With the exception of Laboratories 1 and 3 (described
below), gross deletioneduplication analysis was performed
using an MLPA kit (P015-D2; MRC Holland, Amsterdam,
The Netherlands).
Array CGH and PCR Dosage Analysis
At Laboratory 1 (Round 1 only), genomic DNA from these
cell lines was examined by array-based CGH, using the
current version of ExonArrayDx (Agilent Technologies,
Santa Clara, CA). This custom-designed array contains
DNA oligonucleotide probes that cover all exons and in-
trons of the MECP2 gene and was designed to detect most
single-exon deletions and duplications.The Journal of Molecular Diagnostics - jmd.amjpathol.orgAt Laboratory 3 (Rounds 1 and 2), dosage analysis was
performed, in addition to DNA sequencing. Fragments
sampling the four exons and proximal promoter of the
MECP2 gene, amelogenin and two autosomal gene frag-
ments, were ampliﬁed in a single multiplex polymerase
chain reaction (PCR) in the presence of ﬂuorescently-
labeled primers. Products of the ampliﬁcation reactions
were analyzed on an Applied Biosystems automated capil-
lary DNA sequencer (Life Technologies, Carlsbad, CA).
Dosage analysis was performed using SeqPilot software
version 3.1.0.2 (JSI medical systems, Kippenheim,
Germany).Results
Thegoal of this studywas to generate a comprehensive panel of
publicly available characterized genomic DNA reference ma-
terials for Rett syndrome genetic testing. We sought to include
the eight most common MECP2 point mutations, p.R106W,
p.R168X, p.R255X, p.T158M, p.R306C, p.R294X, p.R270X,277
Kalman et aland p.R133C (referenced at NM_004992.3 and NM_
001110792.1),6 which affect approximately 60% of patients
with Rett syndrome. In addition, we generated cell lines with
other common point mutations, deletions, and duplications
known to cause this disorder. Although Rett syndrome is
most common in females, we included two samples from
males with MECP2 mutations.
We ﬁrst selected eight cell lines derived from patients
with Rett syndrome from the NIGMS Repository at the
Coriell Cell Repositories. These lines, which contain six of
the eight most common mutations that cause Rett syndrome
(as well as one additional point mutation, p.S134C, and one
deletion of MECP2 exons 3 and 4), were tested by DNA
sequence analysis and deletioneduplication analysis at seven
laboratories (Round 1) (Table 1). The mutation previously
identiﬁed in each cell line was conﬁrmed, and results were
concordant among laboratories and assay platforms (Table 1).
In Round 2, DNA from 27 newly generated cell lines was
sent to six volunteer clinical laboratories for analysis (Round
2). DNA from 3 of the original 30 cell lines was not used,
either because it was not available when the study began or
because the expected mutation could not be conﬁrmed during
initial analysis before the study. TheDNAsamples inRound 2
were each tested by two or three laboratories using DNA
sequence analysis and an assay to determine gene dosage
(MLPA or dosage PCR) (Table 2). The results conﬁrmed the
expected genotype (based on information from the submitter)
of the sample andwere concordant among all laboratories and
assay platforms (Table 2).Discussion
DNA samples from 8 Rett syndrome cell lines in the Coriell
Cell Repository and 27 newly generated cell lines were
tested at from two to ﬁve separate clinical genetic testing
laboratories for MECP2 mutations using DNA sequence
analysis and methods to assess copy number (MLPA,
semiquantitative PCR, or array CGH). We identiﬁed sam-
ples with all eight of the common point mutations (listed
under Results) known to cause approximately 60% of Rett
syndrome cases, as well as a number of other MECP2
variants, including deletions, duplications, frame shifts, and
splice site mutations. Two of the samples tested were from
males with duplications in MECP2 gene. The results were
concordant among laboratories and assay platforms.
Molecular diagnosis is critical for diagnosis of patients
with MECP2-related disorders. The Rett syndrome pheno-
type usually becomes apparent at about 18 months of age,
but the timing varies among individuals. Physicians use the
particular combination of symptoms to classify patients into
classic Rett syndrome or variant Rett syndrome.6 Some
patients with variant Rett syndrome may have mutations in
CDKL5,19 and patients with mutations in FOXG1 have
a congenital form of Rett syndrome.1 Genetic testing can
help to conﬁrm or establish the diagnosis in many cases,278especially when the patients are young and the phenotype
may not be completely apparent.4,5 Testing may also be
important for at-risk relatives and for prenatal diagnosis or
preimplantation genetic diagnosis.
To date, there are no commercially available reference
materials or assays for Rett syndrome genetic testing. In the
absence of FDA-approved Rett syndrome assays, clinical
laboratories that test for this disorder must develop and
validate their own assays. This involves not only the design
of the assay, but also the establishment of performance
characteristics such as accuracy, precision, analytical sensi-
tivity, and analytical speciﬁcity. Establishment of these
metrics requires the use of well-characterized reference ma-
terials encompassing the wide variety of variant types that
can be expected in the patient population. In addition, clinical
laboratories must also perform quality-control measures and
participate in proﬁciency testing or other alternative assess-
ment activities, as mandated by regulatory requirements and
professional guidelines (College of American Pathologists
http://www.cap.org/apps/cap.portal, last accessed January
11, 2013; Washington State Legislature, http://www.doh.wa.
gov/hsqa/fsl/lqa_home.htm, last accessed January 11, 2013;
New York State Clinical Laboratory Evaluation Program,
http://www.wadsworth.org/clep, last accessed January 11,
2013).9,10 All of these assay development, validation, and
quality-assurance activities require the use of characterized
reference materials. The reference materials for Rett syn-
drome should contain, in both male and female genomes, the
variants that the assays are designed to detect (eg, point
mutations, deletions, and duplications). This allows labora-
tories to make sure that their assays are robust and have
sufﬁcient sensitivity to detect relevant variants in patients
with Rett syndrome.
Clinical laboratories and proﬁciency test providers often use
genomic DNA from residual patient specimens and available
cell lines, because publicly available reference materials for
Rett syndrome testing are lacking. This approach, although
necessary at present, is not ideal. Residual patient specimens
are usually nonrenewable and of limited supply, and both re-
sidual DNA and cell lines may not be completely character-
ized. For example, several of the cell lines initially evaluated
for this project did not contain the expectedMECP2 mutation
based on information provided by the submitter. Laboratories
may also have difﬁculty obtaining the variety of residual
specimens necessary to adequately represent the spectrum of
common point mutations and deletions and duplications that
occur in Rett syndrome patients.
Cell lines previously available from the Coriell Cell Re-
positories represented only limited Rett syndrome genotypes.
The panel of 35 publicly available genomic DNA samples
developed and characterized as part of this study contains a
wide variety of deletions and duplications in both male and
female samples that can be used by clinical laboratories to
assure the quality of Rett syndrome testing. In addition, the
two samples from male patients allow laboratories to assess
their ability to detect mutations when present in the haploidjmd.amjpathol.org - The Journal of Molecular Diagnostics
Reference Materials for Rett Syndromestate. These and other characterized genomicDNA samples are
publicly available from the NIGMS Repository at the Coriell
Cell Repositories (Camden, NJ). More information about the
CDC GeT-RM program and other genomic DNA reference
materials are available at the GeT-RM website (http://wwwn.
cdc.gov/dls/genetics/RMMaterials, last accessed January 8,
2014).
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